
---
title: 'NLRP1炎症小体内源性抑制剂DPP9'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://picsum.photos/400/300?random=9272'
author: 科学网
comments: false
date: Wed, 21 Sep 2022 16:10:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=9272'
---

<div>   
<p style="margin-top:0;margin-right:0;margin-bottom:0;margin-left:0;text-indent:28px;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:200%"><span style="color: #2A2B2E; font-family: "Segoe UI"; letter-spacing: 0px; font-size: 18px;">二肽基肽酶（</span><span style="background-color: #FCFDFE; color: #2A2B2E; font-family: "Segoe UI"; letter-spacing: 0px;">DPPs</span><span style="color: #2A2B2E; font-family: "Segoe UI"; letter-spacing: 0px; font-size: 18px;">）是在大多数细胞类型的表面上表达的一类抗原酶，与免疫调节、信号转导和凋亡相关。</span><span style="background-color: #FCFDFE; color: #2A2B2E; font-family: "Segoe UI"; letter-spacing: 0px;">DPP</span><span style="color: #2A2B2E; font-family: "Segoe UI"; letter-spacing: 0px; font-size: 18px;">在肿瘤生物学中起重要作用，并且可用作各种癌症的标志物。</span><br></p><p style=";text-indent: 28px;padding: 0;line-height: 200%"><span style="font-size: 18px;"><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">这类分子中最著名的是</span><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;"><span style="font-size: 18px; font-family: "Segoe UI";">在葡萄糖代谢中起主要作用的</span>DPP-4</span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">，</span><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;">DPP-4<span style="font-size: 18px; font-family: "Segoe UI";">通过切割胰高血糖素样肽</span>-1<span style="font-size: 18px; font-family: "Segoe UI";">（</span>GLP-1<span style="font-size: 18px; font-family: "Segoe UI";">）和肠促胰岛素样多肽（</span>GIP<span style="font-size: 18px; font-family: "Segoe UI";">）在葡萄糖代谢中发挥重要作用。</span>DPP-4<span style="font-size: 18px; font-family: "Segoe UI";">抑制剂能够抑制</span>GLP-1<span style="font-size: 18px; font-family: "Segoe UI";">和</span>GIP<span style="font-size: 18px; font-family: "Segoe UI";">被</span>DDP-4<span style="font-size: 18px; font-family: "Segoe UI";">灭活，提高内源性</span>GLP-1<span style="font-size: 18px; font-family: "Segoe UI";">和</span>GIP<span style="font-size: 18px; font-family: "Segoe UI";">的水平，促进胰岛β细胞释放胰岛素，降低血糖。目前在我国上市的</span>DPP-4<span style="font-size: 18px; font-family: "Segoe UI";">抑制剂有西格列汀、阿格列汀、维格列汀、利格列汀和沙格列汀。</span></span></span></p><p style=";text-indent: 28px;padding: 0;line-height: 200%"><span style="font-size: 18px;"><span style="font-family: 宋体; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;"><span style="font-size: 18px; font-family: 宋体;">另外一种</span><span style="font-size: 18px; font-family: "Segoe UI";">DPP9</span><span style="font-size: 18px; font-family: 宋体;">是最近研究热点，最近《科学》杂志上发表了一篇研究，证明这种分子是</span></span><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;">NLRP1炎症小体</span><span style="font-family: 宋体; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;"><span style="font-size: 18px; font-family: 宋体;">内源性抑制剂。和</span><span style="font-size: 18px; font-family: "Segoe UI";">DPP4</span><span style="font-size: 18px; font-family: 宋体;">不太一样的是，</span><span style="font-size: 18px; font-family: "Segoe UI";">DPP9</span><span style="font-size: 18px; font-family: 宋体;">是有利的功能分子，属于</span></span><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;">NLRP1炎症小体</span><span style="font-family: 宋体; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;"><span style="font-size: 18px; font-family: 宋体;">激活刹车。既然是这样，治疗糖尿病的</span><span style="font-size: 18px; font-family: "Segoe UI";">DPP4</span><span style="font-size: 18px; font-family: 宋体;">抑制剂会不会阻断</span></span><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;">DPP9</span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">作用，从而导致</span><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;">NLRP1炎症小体</span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">激活。有意思的是，有研究提示，</span><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;"><span style="font-size: 18px; font-family: 宋体;">通过对</span>DPP-4</span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">抑制剂</span><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;"><span style="font-size: 18px; font-family: 宋体;">使用过程中出现的</span>86<span style="font-size: 18px; font-family: 宋体;">例</span></span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">炎症性肠病</span><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;"><span style="font-size: 18px; font-family: 宋体;">不良反应的研究，发现使用</span>DPP-4</span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">抑制剂</span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">与罹患</span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">炎症性肠病</span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">之间存在着弱相关性</span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">，</span><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;"><span style="font-size: 18px; font-family: 宋体;">一项回顾性队列研究发现，与其他降糖药物相比，使用</span>DPP-4</span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">抑制剂</span><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;"><span style="font-size: 18px; font-family: 宋体;">降糖</span>1.6<span style="font-size: 18px; font-family: 宋体;">年与</span></span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">炎症性肠病</span><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; font-size: 16px; background: #FCFDFE;">IBD<span style="font-size: 18px; font-family: 宋体;">的发生风险具有显著相关性</span></span><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;">。</span></span></p><p style=";text-indent: 28px;padding: 0;line-height: 200%"><span style="font-size: 18px;"><span style="color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px; font-family: 宋体;"><a href="https://www.science.org/doi/10.1126/sciimmunol.abi4611" target="_blank">DPP9 deficiency: An inflammasomopathy that can be rescued by lowering NLRP1/IL-1 signaling | Science Immunology</a></span></span></p><p style="margin-top:0;margin-right:0;margin-bottom:0;margin-left:0;text-indent:28px;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px;">NLRP1炎症小体是一种蛋白质复合体，对各种免疫反应至关重要;因此，其失调可导致严重的免疫紊乱。在本文中，Harapas等研究了4例患二肽基肽酶9 (DPP9)失活突变的儿童，结果表明这些患者有各种免疫紊乱，并且其分离的角质形成细胞中NLRP1炎症小体自发激活。他们利用具有催化非活性DPP9突变的小鼠模型对这些患者进行了建模，发现敲除NLRP1也可以挽救新生儿的死亡率。在斑马鱼模型中，敲除NLRP1炎症小体形成的分子asc也挽救了dpp9敲除斑马鱼的生存。因此，DPP9突变可能导致NLRP1炎症小体过度激活导致免疫紊乱。 </span></p><p style="margin-top:0;margin-right:0;margin-bottom:0;margin-left:0;text-indent:28px;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:200%"><span style="font-family: "Segoe UI"; color: #2A2B2E; letter-spacing: 0px; background: #FCFDFE; font-size: 18px;">二肽基肽酶9 (DPP9)是NLRP1的直接抑制剂，但其如何影响体内炎症小体的调节尚不明确。我们在本文中报告了3个有免疫相关缺陷、生长不良、全血细胞减少和皮肤色素沉着异常的家族，这些家族与双等位基因DPP9罕见变异分离。利用患者来源的原代细胞和生化测定，这些变异体表现为不能抑制NLRP1的低形态或敲除等位基因。去除Nlrp1a/b/c, Asc, Gsdmd或Il-1r的单个拷贝，但不去除Il-18，足以挽救Dpp9突变的新生小鼠的死亡率。同样，在斑马鱼中，NLRP1炎症小体的特异性下游接头asc的失活可以部分挽救dpp9缺陷。这些实验表明，DPP9缺乏的有害后果主要是由典型NLRP1炎症小体和IL-1β信号的异常激活驱动的。总之，我们的结果描述了一种由NLRP1活性增加驱动的DPP9缺乏症，正如在患者细胞和两种疾病动物模型中所证明的那样。</span></p><p style="margin-left:0;text-indent:28px;text-autospace:ideograph-numeric;line-height:200%"><span style="font-size: 18px;"><span style="font-family: Calibri; line-height: 200%; font-size: 16px;"><span style="font-size: 18px; font-family: 宋体;">人类</span>NLRP1 (NLR family pyrin domain containing 1)<span style="font-size: 18px; font-family: 宋体;">炎症小体是一种多蛋白复合体，由病毒感染或危险相关信号触发，导致促炎细胞因子的释放，包括白细胞介素</span><span style="font-size: 18px; font-family: Calibri;">-1 (IL-1)</span><span style="font-size: 18px; font-family: 宋体;">家族成员</span><span style="font-size: 18px; font-family: Calibri;">IL-1β</span><span style="font-size: 18px; font-family: 宋体;">和</span><span style="font-size: 18px; font-family: Calibri;">IL-18</span><span style="font-size: 18px; font-family: 宋体;">。人类</span><span style="font-size: 18px; font-family: Calibri;">NLRP1</span><span style="font-size: 18px; font-family: 宋体;">炎症小体的失调与一系列孟德尔炎症性疾病相关，如多种自愈性掌跖癌</span><span style="font-size: 18px; font-family: Calibri;">(MIM615225)</span><span style="font-size: 18px; font-family: 宋体;">。幼年复发性呼吸道乳头状瘤病</span><span style="font-size: 18px; font-family: Calibri;">(juvenile recurrent respiratory papillomatosis, MIM618803)(6</span><span style="font-size: 18px; font-family: 宋体;">例</span><span style="font-size: 18px; font-family: Calibri;">)</span><span style="font-size: 18px; font-family: 宋体;">和自身炎症伴关节炎和角化不良</span><span style="font-size: 18px; font-family: Calibri;">(AIADK;</span><span style="font-size: 18px; font-family: 宋体;">在没有任何同源触发器的情况下，</span><span style="font-size: 18px; font-family: Calibri;">nod</span><span style="font-size: 18px; font-family: 宋体;">样受体家族中的炎症小体感受器通过一些调节蛋白维持在非活性状态。例如，</span><span style="font-size: 18px; font-family: Calibri;">NLRP1</span><span style="font-size: 18px; font-family: 宋体;">与二肽基肽酶</span><span style="font-size: 18px; font-family: Calibri;">9 (DPP9)</span><span style="font-size: 18px; font-family: 宋体;">和</span><span style="font-size: 18px; font-family: Calibri;">DPP8</span><span style="font-size: 18px; font-family: 宋体;">的酶活性和支架功能结合并被其抑制。最近的</span></span><strong><span style="font-family: Calibri; line-height: 200%; color: #0000FF; font-size: 16px;"><span style="font-size: 18px; font-family: 宋体;">冷冻电子显微镜研究表明，</span>DPP9<span style="font-size: 18px; font-family: 宋体;">通过直接结合</span><span style="font-size: 18px; font-family: Calibri;">NLRP1- fiind (function-to-find domain)</span><span style="font-size: 18px; font-family: 宋体;">结构域来抑制</span><span style="font-size: 18px; font-family: Calibri;">NLRP1</span><span style="font-size: 18px; font-family: 宋体;">的激活</span></span></strong><span style="font-family: Calibri; line-height: 200%; font-size: 16px;"><span style="font-size: 18px; font-family: 宋体;">。</span>DPP9<span style="font-size: 18px; font-family: 宋体;">二聚体的单个单体与</span><span style="font-size: 18px; font-family: Calibri;">NLRP1</span><span style="font-size: 18px; font-family: 宋体;">的两个分子结合，其中一个分子作为全长分子存在，而另一个是剪切的</span><span style="font-size: 18px; font-family: Calibri;">UPA-CARD (UNC5</span><span style="font-size: 18px; font-family: 宋体;">、</span><span style="font-size: 18px; font-family: Calibri;">PIDD</span><span style="font-size: 18px; font-family: 宋体;">、锚蛋白</span><span style="font-size: 18px; font-family: Calibri;">-</span><span style="font-size: 18px; font-family: 宋体;">半胱天冬酶募集域</span><span style="font-size: 18px; font-family: Calibri;">)</span><span style="font-size: 18px; font-family: 宋体;">片段。因此，</span><span style="font-size: 18px; font-family: Calibri;">DPP9</span><span style="font-size: 18px; font-family: 宋体;">在全长</span><span style="font-size: 18px; font-family: Calibri;">NLRP1</span><span style="font-size: 18px; font-family: 宋体;">分子的帮助下，隔离了具有生物活性的</span><span style="font-size: 18px; font-family: Calibri;">NLRP1 c</span><span style="font-size: 18px; font-family: 宋体;">端片段，从而阻止炎症小体的形成。</span></span><strong><span style="font-family: Calibri; line-height: 200%; color: #0000FF; font-size: 16px;">DPP9<span style="font-size: 18px; font-family: 宋体;">作为人类或小鼠</span><span style="font-size: 18px; font-family: Calibri;">NLRP1</span><span style="font-size: 18px; font-family: 宋体;">的负性调节因子的作用已经在体外通过药物抑制</span><span style="font-size: 18px; font-family: Calibri;">DPP9</span><span style="font-size: 18px; font-family: 宋体;">和在细胞系中灭活</span><span style="font-size: 18px; font-family: Calibri;">DPP9</span><span style="font-size: 18px; font-family: 宋体;">而被证实，但其在体内的功能尚未被证实。</span></span></strong></span></p><p style="margin-left: 0px; text-indent: 28px; line-height: 200%;"><span style="font-size: 18px;"><strong><span style="line-height: 200%; font-size: 18px; font-family: 宋体;">在本研究中，</span></strong><span style="font-family: Calibri; line-height: 200%; font-size: 16px;"><span style="font-size: 18px; font-family: 宋体;">我们发现了</span>4<span style="font-size: 18px; font-family: 宋体;">例具有免疫相关缺陷和皮肤色素沉着异常，并且携带</span><span style="font-size: 18px; font-family: Calibri;">DPP9</span><span style="font-size: 18px; font-family: 宋体;">失活突变的儿童。</span></span><strong><span style="font-family: Calibri; line-height: 200%; color: #0000FF; font-size: 16px;"><span style="font-size: 18px; font-family: 宋体;">患者的角质形成细胞表现出</span>NLRP1<span style="font-size: 18px; font-family: 宋体;">炎症小体的自发激活。</span></span></strong><span style="font-family: Calibri; line-height: 200%; font-size: 16px;"><span style="font-size: 18px; font-family: 宋体;">我们使用携带使蛋白质失去催化活性的</span>DPP9<span style="font-size: 18px; font-family: 宋体;">突变</span><span style="font-size: 18px; font-family: Calibri;">(Dpp9S759A/S759A)</span><span style="font-size: 18px; font-family: 宋体;">的小鼠模型来模拟这一情况。</span><span style="font-size: 18px; font-family: Calibri;">Dpp9S759A/S759A</span><span style="font-size: 18px; font-family: 宋体;">小鼠在出生后</span><span style="font-size: 18px; font-family: Calibri;">1</span><span style="font-size: 18px; font-family: 宋体;">天内死亡，死亡机制不明。我们发现，将</span><span style="font-size: 18px; font-family: Calibri;">Dpp9S759A/S759A</span><span style="font-size: 18px; font-family: 宋体;">小鼠与</span><span style="font-size: 18px; font-family: Calibri;">Nlrp1</span><span style="font-size: 18px; font-family: 宋体;">敲除</span><span style="font-size: 18px; font-family: Calibri;">(KO)</span><span style="font-size: 18px; font-family: 宋体;">小鼠</span><span style="font-size: 18px; font-family: Calibri;">(Nlrp1 - / -)</span><span style="font-size: 18px; font-family: 宋体;">杂交后，可以在不完全外显的情况下挽救新生儿死亡率。一些小鼠的表型改善表明，</span></span><strong><span style="font-family: Calibri; line-height: 200%; color: #0000FF; font-size: 16px;">DPP9<span style="font-size: 18px; font-family: 宋体;">的生理作用是阻止</span><span style="font-size: 18px; font-family: Calibri;">NLRP1</span><span style="font-size: 18px; font-family: 宋体;">炎症小体的组装。</span></span></strong><span style="font-family: Calibri; line-height: 200%; font-size: 16px;"><span style="font-size: 18px; font-family: 宋体;">此外，我们还表明，在某些情况下，通过缺失</span>NLRP1<span style="font-size: 18px; font-family: 宋体;">炎症小体的下游成分也可以挽救</span><span style="font-size: 18px; font-family: Calibri;">Dpp9S759A/S759A</span><span style="font-size: 18px; font-family: 宋体;">新生儿死亡率。同样地，我们发现</span><span style="font-size: 18px; font-family: Calibri;">dpp9 KO</span><span style="font-size: 18px; font-family: 宋体;">斑马鱼的早期死亡率也可以通过伴随的</span><span style="font-size: 18px; font-family: Calibri;">pycard[</span><span style="font-size: 18px; font-family: 宋体;">包含</span><span style="font-size: 18px; font-family: Calibri;">PYD</span><span style="font-size: 18px; font-family: 宋体;">和</span><span style="font-size: 18px; font-family: Calibri;">CARD</span><span style="font-size: 18px; font-family: 宋体;">结构域的蛋白，也被称为</span><span style="font-size: 18px; font-family: Calibri;">asc(</span><span style="font-size: 18px; font-family: 宋体;">凋亡斑点样蛋白包含</span><span style="font-size: 18px; font-family: Calibri;">CARD)]</span><span style="font-size: 18px; font-family: 宋体;">的失活来部分挽救，</span><span style="font-size: 18px; font-family: Calibri;">pycard</span><span style="font-size: 18px; font-family: 宋体;">是</span><span style="font-size: 18px; font-family: Calibri;">NLRP1</span><span style="font-size: 18px; font-family: 宋体;">炎症小体的一个专门的下游接头。总之，我们在体内证明了</span></span><strong><span style="font-family: Calibri; line-height: 200%; color: #0000FF; font-size: 16px;">DPP9<span style="font-size: 18px; font-family: 宋体;">抑制</span><span style="font-size: 18px; font-family: Calibri;">NLRP1</span><span style="font-size: 18px; font-family: 宋体;">炎症小体激活的重要性，在人类和两个动物模型中，</span><span style="font-size: 18px; font-family: Calibri;">DPP9</span><span style="font-size: 18px; font-family: 宋体;">缺乏导致了</span><span style="font-size: 18px; font-family: Calibri;">NLRP1</span><span style="font-size: 18px; font-family: 宋体;">驱动的炎症性疾病。</span></span></strong></span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自孙学军科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-41174-1356300.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-41174-1356300.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-41174-1356104.html" target="_black">科学应该不难理解！</a><br>下一篇：<a href="http://blog.sciencenet.cn/blog-41174-1356453.html" target="_black">学术界近亲繁殖是常态！</a>                    <!--大赛结束-->
                                        
  
</div>
            